Marfan Sartan: a randomized, double-blind, placebo-controlled trial
Top Cited Papers
- 2 May 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 36 (32), 2160-2166
- https://doi.org/10.1093/eurheartj/ehv151
Abstract
Aims To evaluate the benefit of adding Losartan to baseline therapy in patients with Marfan syndrome (MFS). Methods and results A double-blind, randomized, multi-centre, placebo-controlled, add on trial comparing Losartan (50 mg when 10 years old, and receiving standard therapy. 303 patients, mean age 29.9 years old, were randomized. The two groups were similar at baseline, 86% receiving β-blocker therapy. The median follow-up was 3.5 years. The evolution of aortic diameter at the level of the sinuses of Valsalva was not modified by the adjunction of Losartan, with a mean increase in aortic diameter at the level of the sinuses of Valsalva of 0.44 mm/year (s.e. = 0.07) (−0.043 z/year, s.e. = 0.04) in patients receiving Losartan and 0.51 mm/year (s.e. = 0.06) (−0.01 z/year, s.e. = 0.03) in those receiving placebo (P = 0.36 for the comparison on slopes in millimeter per year and P = 0.69 for the comparison on slopes on z-scores). Patients receiving Losartan had a slight but significant decrease in systolic and diastolic blood pressure throughout the study (5 mmHg). During the study period, aortic surgery was performed in 28 patients (15 Losartan, 13 placebo), death occurred in 3 patients [0 Losartan, 3 placebo, sudden death (1) suicide (1) oesophagus cancer (1)]. Conclusion Losartan was able to decrease blood pressure in patients with MFS but not to limit aortic dilatation during a 3-year period in patients >10 years old. β-Blocker therapy alone should therefore remain the standard first line therapy in these patients.Keywords
This publication has 34 references indexed in Scilit:
- Aortic Event Rate in the Marfan PopulationCirculation, 2012
- The new Ghent criteria for Marfan syndrome: what do they change?Clinical Genetics, 2011
- Angiotensin II Type 2 Receptor Signaling Attenuates Aortic Aneurysm in Mice Through ERK AntagonismScience, 2011
- Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndromeArchives of Cardiovascular Diseases, 2010
- 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic DiseaseCirculation, 2010
- Long-term effects of losartan on structure and function of the thoracic aorta in a mouse model of Marfan syndromeBritish Journal of Pharmacology, 2009
- Identification of the minimal combination of clinical features in probands for efficient mutation detection in the FBN1 geneEuropean Journal of Human Genetics, 2009
- Angiotensin II Blockade and Aortic-Root Dilation in Marfan's SyndromeThe New England Journal of Medicine, 2008
- Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan SyndromeScience, 2006
- Two-dimensional echocardiographic aortic root dimensions in normal children and adultsThe American Journal of Cardiology, 1989